$IRIX

IRIDEX Corporation reported its Q1 2026 earnings, with revenues of $11.8 million, essentially flat year-over-year, and beating EPS expectations with a reported $-0.03 against an expected $-0.07. The company's glaucoma business, particularly G-Probes, showed strong growth, but international retina sales were impacted by regulatory and supply chain issues. Despite these challenges, IRIDEX reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million and expects to achieve positive cash flow from operations for the full year.